推荐产品
等级
pharmaceutical primary standard
API类
cholecalciferol
制造商/商品名称
USP
mp
83-86 °C (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
−20°C
SMILES字符串
CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C
InChI
1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
InChI key
QYSXJUFSXHHAJI-YRZJJWOYSA-N
基因信息
human ... VDR(7421)
正在寻找类似产品? 访问 产品对比指南
一般描述
本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。
应用
Cholecalciferol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Cholecalciferol Solution
- Cholecalciferol Capsules
- Cholecalciferol Tablets
- Cholecalciferol Chewable Gels
- Calcium with Vitamin D Tablets
- Oil-Soluble Vitamins Preparation
生化/生理作用
维生素 D 借以发挥作用的受体是配体依赖性转录因子超家族的成员。调控正常细胞和癌细胞的增殖和分化。对乳腺癌、结肠癌和前列腺癌细胞具有抗增殖和抗转移作用。肠和骨骼中的活化维生素 D 受体维持着钙的吸收和平衡。
维生素 D 通过调控正常细胞和癌细胞增殖和分化的受体而发挥作用。
分析说明
这些产品仅供测试和分析使用。它们不适用于人类或动物的给药，不可用于诊断、治疗或治愈任何疾病。
其他说明
可能适用相应的销售限制。
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral
储存分类代码
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Cholecalciferol Tablets
United States Pharmacopeia, 43(2), 988-988 (2018)
Cholecalciferol Solution
United States Pharmacopeia, 987-987 (2013)
Cholecalciferol
United States Pharmacopeia, 44(6), 985-985 (2020)
Robin M Daly et al.
The American journal of clinical nutrition, 99(4), 899-910 (2014-01-31)
Physical inactivity, inadequate dietary protein, and low-grade systemic inflammation contribute to age-related muscle loss, impaired function, and disability. We assessed the effects of progressive resistance training (PRT) combined with a protein-enriched diet facilitated through lean red meat on lean tissue
Sagar U Nigwekar et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 60(1), 139-156 (2012-05-09)
The development of chronic kidney disease (CKD) is accompanied by a progressive decrease in the ability to produce 1,25-dihydroxyvitamin D. Pharmacological replacement with active vitamin D therefore has been a cornerstone of secondary hyperparathyroidism therapy in the end-stage renal disease
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门